Results for this period
Third quarter1 September 2025 to 31 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Demand for patient wear weakened in peripheral markets, and some renewal projects were delayed, while net sales increased for surgical wear and in overseas markets. The Company pursued cost reductions through price revisions, lower overseas logistics costs and a higher proportion of overseas production.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 September 2025 to 31 May 2026 |
| Net Sales | ¥13,267 million (YoY -0.7%) |
| Operating profit | ¥2,813 million (YoY -3.5%) |
| Ordinary income | ¥2,958 million (YoY -1.2%) |
| Profit attributable to owners of the parent | ¥2,046 million (YoY -1.0%) |
| Net income per share | ¥67.86 |
| Equity ratio | End of the current fiscal period 92.3 / End of previous period 92.5 |
| Total assets | ¥42,725 million |
| Net assets | ¥39,424 million |
| Full-year earnings forecast | Net Sales ¥18,000 million (YoY +6.0%) / Operating profit ¥4,025 million (YoY +12.3%) / Ordinary income ¥4,200 million (YoY +13.3%) / Profit attributable to owners of the parent ¥2,900 million (YoY +12.7%) |
| Revision to Earnings Forecast | Net Sales No / Operating profit No / Ordinary income No / Profit attributable to owners of the parent No |
| Annual Dividend Forecast | ¥100 → ¥70 |
| Depreciation and amortization | ¥220,685 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥10,436 thousand / Extraordinary loss Loss on disposal and sale of non-current assets ¥156 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added 0 companies; removed 0 companies. |
| Material subsequent events | At a meeting of the Board of Directors held on 29 June 2026, the Company resolved to acquire up to 600,000 shares of treasury stock through market purchases from 30 June 2026 to 31 October 2026, with an aggregate acquisition price capped at ¥1 billion. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 30,736,000 |
| Treasury Shares at Period-End | 766,526 |
| Factors Behind Changes in Business Performance | Demand for patient wear weakened in peripheral markets, and some renewal projects were delayed, while net sales increased for surgical wear and in overseas markets. The Company pursued cost reductions through price revisions, lower overseas logistics costs and a higher proportion of overseas production. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Demand for patient wear in peripheral markets weakened due to changes in market conditions and the impact of price revisions, which was the main factor behind the overall decline in revenue. In the core markets, some renewal projects were delayed due to negotiations over price revisions and heightened tensions in the Middle East. Raw material prices, processing costs and labor costs also continued to rise. No reason was stated for the revision to the dividend forecast.